tegaserod agonist manufactured novartis sold names zelnorm zelmac management irritable bowel syndrome approved fda subsequently removed market due fda concerns possible adverse cardiovascular effects drug approved united states food drug administration help relieve abdominal discomfort bloating constipation associated irritable bowel syndrome use also approved treat chronic idiopathic drug functions motility stimulant achieving desired therapeutic effects activation receptors enteric nervous system gastrointestinal tract also stimulates gastrointestinal motility peristaltic reflex allegedly reduces abdominal additionally tegaserod receptor march united states food drug administration requested novartis withdraw tegaserod fda alleged relationship prescriptions drug increased risks heart attack stroke analysis data collected patients demonstrated adverse cardiovascular events patients treated tegaserod rate compared patients treated placebo rate novartis alleged affected patients preexisting cardiovascular disease risk factors alleged causal relationship tegaserod use cardiovascular events day fda announcement novartis pharmaceuticals canada announced suspending marketing sales drug canada response request health large cohort study based us health insurance database increase risk cardiovascular events found tegaserod tegaserod reintroduced use irritable bowel syndrome constipation ibsc women httpsenwikipediaorgwikitegaserod